| __timestamp | CRISPR Therapeutics AG | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 72049000 |
| Thursday, January 1, 2015 | 12573000 | 110777000 |
| Friday, January 1, 2016 | 42238000 | 156328000 |
| Sunday, January 1, 2017 | 69800000 | 175820000 |
| Monday, January 1, 2018 | 113773000 | 143944000 |
| Tuesday, January 1, 2019 | 179362000 | 160152000 |
| Wednesday, January 1, 2020 | 269407000 | 188519000 |
| Friday, January 1, 2021 | 17953000 | 258234000 |
| Saturday, January 1, 2022 | 110250000 | 311103000 |
| Sunday, January 1, 2023 | 130250000 | 384447000 |
| Monday, January 1, 2024 | -2314000 |
In pursuit of knowledge
In the rapidly evolving biotech sector, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for CRISPR Therapeutics AG and HUTCHMED (China) Limited from 2014 to 2023. Over this period, CRISPR Therapeutics AG saw a dramatic increase in its cost of revenue, peaking in 2020 with a staggering 1,680% rise from its 2014 figures. Meanwhile, HUTCHMED (China) Limited experienced a more consistent growth, with its cost of revenue increasing by approximately 434% over the same period, reaching its highest in 2023. This data highlights the differing financial strategies and market conditions faced by these companies. While CRISPR Therapeutics AG's costs fluctuated significantly, HUTCHMED maintained a steadier trajectory, reflecting its strategic positioning in the competitive biotech landscape.
Cost of Revenue Trends: Novartis AG vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Pfizer Inc. vs CRISPR Therapeutics AG
Vertex Pharmaceuticals Incorporated vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and CRISPR Therapeutics AG's Expenses
Cost of Revenue Comparison: Grifols, S.A. vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Ligand Pharmaceuticals Incorporated
CRISPR Therapeutics AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down CRISPR Therapeutics AG and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Xenon Pharmaceuticals Inc. and HUTCHMED (China) Limited
MorphoSys AG vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: HUTCHMED (China) Limited vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for HUTCHMED (China) Limited and MiMedx Group, Inc.